Global Wearable Continuous Glucose Monitors Market - 2025-2033

The global wearable continuous glucose monitors (CGM) market reached US$ 4.57 billion in 2024 and is expected to reach US$ 16.60 billion by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Wearable Continuous Glucose Monitors (CGMs) are advanced medical devices used to monitor glucose levels in real time. They provide continuous, real-time data on glucose fluctuations throughout the day, offering a more detailed and consistent picture of glucose levels compared to traditional blood glucose meters that provide single-point readings.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The significant rise in the global prevalence of diabetes is driving the growth of the wearable continuous glucose monitoring (CGM) devices market. The number of people living with diabetes has increased dramatically, from 200 million in 1990 to 830 million in 2022, with the most rapid rise occurring in low- and middle-income countries according to the World Health Organization. As the prevalence of diabetes grows, the need for effective, real-time monitoring of glucose levels becomes even more critical. Wearable CGMs offer an efficient, non-invasive solution for continuous glucose monitoring, helping patients better manage their condition and reduce the risk of severe complications.

The impact of untreated or poorly managed diabetes is severe, leading to conditions such as blindness, kidney failure, heart attacks, strokes, and lower limb amputations. In 2021 alone, diabetes and diabetes-related kidney disease were responsible for over 2 million deaths, with high blood glucose contributing to around 11% of cardiovascular deaths. Given these statistics, the demand for continuous glucose monitoring devices is expected to increase as healthcare systems and patients seek more proactive ways to manage diabetes and prevent life-threatening complications.

Wearable CGMs are becoming increasingly vital in providing individuals with real-time data that can inform timely interventions, reduce the risk of complications, and improve the overall quality of life for people with diabetes. This growing need for diabetes management is a key factor driving the expansion of the wearable CGM market.

High Sensor Replacement Costs

The short sensor lifespan and replacement costs of wearable continuous glucose monitoring (CGM) devices can significantly restrain the market by creating a financial burden for consumers. Most CGM sensors need to be replaced every 7 to 14 days, resulting in frequent ongoing expenses that can quickly add up, making long-term use costly.

Segment Analysis

The global wearable continuous glucose monitors (CGM) market is segmented based on type, components, age group, end-user, and region.

Product Type:

Sensors segment is expected to dominate the global wearable continuous glucose monitors (cgm) market share

The sensors component segment is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to their essential role in providing real-time, accurate glucose measurements. Sensors are the core technology behind CGMs, as they continuously monitor blood glucose levels through interstitial fluid, offering users detailed and up-to-date information. With the increasing demand for more precise, real-time monitoring, advancements in sensor technology have enabled the development of more accurate, smaller, and longer-lasting devices.

Moreover, innovations in sensor design, such as improved accuracy, reduced size, and extended wear times, are driving the segment's growth. As people with diabetes seek more efficient and convenient ways to manage their condition, the demand for CGM systems with advanced sensors is growing. This makes the sensors segment a key driver in the wearable CGM market, as it directly impacts the overall performance and reliability of these devices.

Geographical Analysis

North America is expected to hold a significant position in the global wearable continuous glucose monitors (CGM) market share

North America is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to a combination of factors. The increasing technological advancements, rising number of diabetic patients, and increasing number of product launches are expected to hold the region in the dominant position in the global market.

The region has a high prevalence of diabetes, driving the demand for advanced diabetes management solutions. The high incidence of diabetes in North America, particularly in the United States, is significantly driving the demand for wearable continuous glucose monitoring (CGM) devices. In 2021, an estimated 29.7 million people, or 8.9% of the U.S. population, were diagnosed with diabetes. This growing prevalence, including 352,000 children and adolescents under the age of 20, highlights the urgent need for effective and convenient ways to monitor glucose levels continuously. As the number of diabetes cases continues to rise, the demand for solutions like CGMs, which provide real-time, accurate glucose data and help individuals manage their condition more effectively.

Additionally, market players are increasingly innovating the advanced wearable CGMs that are gaining approvals from the Food and Drug Administration (FDA). For instance, in March and June 2024, Dexcom and Abbott received clearance from the Food and Drug Administration (FDA) for their over-the-counter (OTC) continuous glucose monitors. While these devices utilize the same hardware as previous CGMs, they are designed for a different group of users, individuals who do not require insulin. Increasing approvals for products, such as over-the-counter continuous glucose monitors from companies are expected to drive the North American market by expanding accessibility to glucose monitoring solutions. This will cater to a broader range of users, including those without insulin dependence. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the wearable continuous glucose monitors (CGM) market include Afon Technology, Abbott, Senseonics, Ascensia Diabetes Care Holdings AG., A. Menarini Diagnostics srl, Murata Manufacturing Co., Ltd., Dexcom, Inc., Tandem Diabetes Care, Inc., Medtronic and Byram Healthcare Centers, Inc. among others.

Key Developments
• In September 2024, Abbott launched its latest wearable, the Lingo continuous glucose monitor, now available for over-the-counter purchase. Unlike traditional devices designed for diabetics, Lingo is tailored for health-conscious individuals who want to track their glucose levels without requiring prior medical approval.
• In February 2024, Know Labs, Inc. unveiled the KnowU, its wearable non-invasive continuous glucose monitor (CGM). The company first introduced the prototype in June 2023, with the KnowU being the outcome of an accelerated eight-month development process.
• In January 2025, Samsung announced that it is developing a highly anticipated feature for wearable technology: a non-invasive continuous glucose monitor.
• In April 2024, Senseonics Holdings, Inc. announced that their Eversense device has received the integrated CGM (iCGM) designation from the U.S. Food and Drug Administration (FDA).

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Wearable Continuous Glucose Monitors (CGM) Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.